FDA approves LHRH implant for treatment of advanced PCa

October 28, 2004

The FDA approved the marketing of a histrelin implant (Vantas) for the palliative treatment of advanced prostate cancer.

The FDA approved the marketing of a histrelin implant (Vantas) for the palliative treatment of advanced prostate cancer. The implant allows 12-month continuous administration of histrelin, which is a synthetic nonapeptide agonist of luteinizing hormone-releasing hormone.

The drug's manufacturer, Valera Pharmaceuticals, said the product uses the company's Hydron Implant technology, which allows for the formulation of highly compact, lightweight, flexible, and retrievable subcutaneous implants that can be administered in a physician's office.